XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2024 | Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax | [1] | $ 62,840 |  | $ 53,473 | $ 178,843 |  | $ 157,283
Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 36,809 |  | 31,209 | 101,740 |  | 88,365
Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 15,796 |  | 12,745 | 45,482 |  | 39,975
Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 10,235 |  | 9,519 | 31,621 |  | 28,943
Operating Segments [Member] | Sterilization and Disinfection Control [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | [1],[2] | 23,507 | [3] | 19,338 | 68,669 | [4] | 52,345
Operating Segments [Member] | Clinical Genomics [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | [1] | 12,667 |  | 12,546 | 35,570 |  | 41,464
Operating Segments [Member] | Biopharmaceutical Development [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | [1] | 12,237 |  | 9,430 | 36,112 |  | 28,526
Operating Segments [Member] | Calibration Solutions [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | [1] | 14,429 |  | 12,159 | 38,492 |  | 34,948
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 20,991 | [3] | 16,832 | 60,860 | [4] | 45,288
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 9,866 |  | 9,758 | 26,156 |  | 28,490
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 4,909 |  | 4,080 | 12,657 |  | 12,753
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 1,043 |  | 539 | 2,067 |  | 1,834
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 52 | [3] | 180 | 365 | [4] | 381
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 1,877 |  | 1,639 | 6,511 |  | 9,540
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 4,534 |  | 2,672 | 14,539 |  | 7,838
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 9,333 |  | 8,254 | 24,067 |  | 22,216
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 2,464 | [3] | 2,326 | 7,444 | [4] | 6,676
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 924 |  | 1,149 | 2,903 |  | 3,434
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | 2,794 |  | 2,678 | 8,916 |  | 7,935
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member] |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  | $ 4,053 |  | $ 3,366 | $ 12,358 |  | $ 10,898
[1] | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] | Includes post-acquisition GKE results during the three and six months ended September 30, 2024.
[3] | Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.
[4] | Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mlab_ConsumablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mlab_HardwareAndSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |